 offers hope to patients, including Ashton Leeds, a 9-year-old boy with stage 4 thyroid cancer, by targeting specific genetic mutations A child with cancer has found hope again thanks to a new drug inhibiting cancer growth newly-approved in the US. The newly-approved cancer drug called Vitrakvi (larotrectinib) has brought hope to many cancer patients, including a 9-year-old boy named Ashton Leeds who had stage 4 thyroid cancer. After undergoing surgeries and traditional treatments that were unsuccessful, Ashton's cancer became resistant to therapy. However, he was able to participate in a clinical trial for Vitrakvi, which targets a specific genetic mutation found in certain cancers. The drug inhibits the protein responsible for cancer growth in these tumours. The FDA approved Vitrakvi after it was studied in three clinical trials involving 176 cancer patients with the specific genetic mutation (NTRK). Ashton's health significantly improved after taking Vitrakvi, and although he is not fully cured, his prognosis is hopeful. The drug works effectively for patients with the applicable mutation and has shown promising results in other cases. Ashton's parents, Kayley Leeds and Shayne Leeds, expressed their gratitude and hope for their son's future after he received treatment with Vitrakvi (larotrectinib). Ms Leeds mentioned that the drug had been the best thing that happened to them in the last couple of years. It gave them hope for Ashton's future, and they felt that everything was going to be okay. Mr Leeds told Good Morning America: "The worst moment was probably seeing him after he had surgery and seeing him hooked up to all the machines." Although Ashton is not completely cured, his prognosis is now considered hopeful, thanks to the positive results they observed after he started taking Vitrakvi. Dr Katie Albert, a pediatric oncologist at Seattle Children's Hospital, explained that Vitrakvi (larotrectinib)){kind=link}
A newly-approved cancer drug called Vitrakvi (larotrectinib) offers hope to patients, including Ashton Leeds, a 9-year-old boy with stage 4 thyroid cancer, by targeting specific genetic mutations
A child with cancer has found hope again thanks to a new drug inhibiting cancer growth newly-approved in the US.
The newly-approved cancer drug called Vitrakvi (larotrectinib) has brought hope to many cancer patients, including a 9-year-old boy named Ashton Leeds who had stage 4 thyroid cancer. After undergoing surgeries and traditional treatments that were unsuccessful, Ashton’s cancer became resistant to therapy.
However, he was able to participate in a clinical trial for Vitrakvi, which targets a specific genetic mutation found in certain cancers. The drug inhibits the protein responsible for cancer growth in these tumours.
The FDA approved Vitrakvi after it was studied in three clinical trials involving 176 cancer patients with the specific genetic mutation (NTRK). Ashton’s health significantly improved after taking Vitrakvi, and although he is not fully cured, his prognosis is hopeful. The drug works effectively for patients with the applicable mutation and has shown promising results in other cases.